ARO-SNCA / Arrowhead Pharmaceuticals, Novartis - LARVOL DELTA

Arrowhead Pharmaceuticals and Novartis Enter into a Global License and Collaboration Agreement (Businesswire) - "Upon closing, Arrowhead will receive an upfront payment of $200 million; Novartis will receive an exclusive worldwide license to ARO-SNCA, Arrowhead’s preclinical stage siRNA therapy for the treatment of synucleinopathies, such as Parkinson’s Disease, plus additional collaboration targets."

Licensing / partnership • Immunology